from Section 3 - Developmental biology
Published online by Cambridge University Press: 05 October 2013
Introduction
Successful infertility treatment, especially in vitro fertilization (IVF) and accompanying clinical and laboratory technologies, has to be one of the great medical success stories of the late twentieth and early twenty-first centuries. In the space of 35 years of development, assisted reproduction through IVF now contributes up to 4% of all births in developed nations, with these figures set to increase further due to the influence of increasing maternal age to first conception, lifestyle choices, and the exposure to environmental toxins. The success of current technology utilized in an IVF cycle is dependent on gonadotropic hormone hyperstimulation of the ovary to generate large numbers of mature oocytes (Figure 18.1). Nevertheless, hormonal stimulation of the ovary by follicle stimulating hormone (FSH), or an analog, is associated with various risks and financial costs. These include: a health risk to women caused by severe ovarian hyperstimulation syndrome (OHSS), which affects 0.5–5% of gonadotropin-treated women [1]; a risk to oocyte and resulting embryo health (e.g., embryo an-euploidy [2] and perturbed genomic imprinting [3]); and a significant financial burden placed on couples and/or healthcare providers due to the cost of the gonadotropin treatment. Furthermore, FSH has dose-dependent adverse effects on subsequent embryo quality, endometrial protein expression, and pregnancy rates in adult, cycling female mice [4, 5]. Therefore, safe, reliable alternatives to the current clinical IVF practices that remove the need for hyperstimulatory FSH treatment, accompanied with increased treatment options for women, is highly attractive. This would be particularly so for women who suffer from the very prevalent condition of polycystic ovaries (estimated to be around 20% of women of reproductive age), who are particularly susceptible to OHSS and as a result, at times have limited IVF treatment options.
To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Find out more about the Kindle Personal Document Service.
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.